262 related articles for article (PubMed ID: 9737837)
1. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
[TBL] [Abstract][Full Text] [Related]
2. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
Gregor KJ; Way K; Young CH; James SP
J Affect Disord; 1997 Oct; 46(1):59-67. PubMed ID: 9387087
[TBL] [Abstract][Full Text] [Related]
3. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
4. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.
Berle JØ; Steen VM; Aamo TO; Breilid H; Zahlsen K; Spigset O
J Clin Psychiatry; 2004 Sep; 65(9):1228-34. PubMed ID: 15367050
[TBL] [Abstract][Full Text] [Related]
5. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.
Berndt ER; Russell JM; Miceli R; Colucci SV; Xu Y; Grudzinski AN
Value Health; 2000; 3(3):208-21. PubMed ID: 16464185
[TBL] [Abstract][Full Text] [Related]
6. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
8. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Polsky D; Onesirosan P; Bauer MS; Glick HA
J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
[TBL] [Abstract][Full Text] [Related]
9. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
Harvey AT; Preskorn SH
J Clin Psychopharmacol; 1996 Oct; 16(5):345-55. PubMed ID: 8889906
[TBL] [Abstract][Full Text] [Related]
11. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
Preskorn SH; Shah R; Neff M; Golbeck AL; Choi J
J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
13. Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.
Dewa CS; Hoch JS; Goering P
Clin Ther; 2001 Feb; 23(2):292-306. PubMed ID: 11293562
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
15. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
[TBL] [Abstract][Full Text] [Related]
16. Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Yunusa I; Gagne JJ; Yoshida K; Bykov K
JAMA Netw Open; 2022 Feb; 5(2):e220194. PubMed ID: 35201310
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
Nelson MH; Birnbaum AK; Remmel RP
Epilepsy Res; 2001 Apr; 44(1):71-82. PubMed ID: 11255075
[TBL] [Abstract][Full Text] [Related]
18. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
Liston HL; DeVane CL; Boulton DW; Risch SC; Markowitz JS; Goldman J
J Clin Psychopharmacol; 2002 Apr; 22(2):169-73. PubMed ID: 11910262
[TBL] [Abstract][Full Text] [Related]
19. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
